Amgen is joining the biopharma exodus out of neurosciences R&D, cutting 180 R&D jobs in reorganization
Three months after Amgen folded up a late-stage Alzheimer’s study of their failed BACE inhibitor partnered with Novartis, the pharma giant is joining the general exodus out of neurosciences. And they’re cutting some 180 positions as a result of the reorganization.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.